EASL Press Conference 2019 Upload video: No flash player has been set up. Please select a player to play Flash videos.
30Sep, 14Press Release, Moscow, October, 2014Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry...
29Oct, 18MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta at the AASLD Meeting in San FranciscoBAD HOMBURG, Germany, October 29, 2018 / PRNewswire / -- MYR Pharma today announced that the results of 48 weeks of...
04Apr, 19MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR´s...
13Apr, 19ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression bILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with...
